Erasca Reports Second Quarter 2021 Financial Results and Business Updates
August 26, 2021 16:01 ET
|
Erasca, Inc.
Successfully closed $345 million upsized IPO in July 2021 On track to initiate multiple HERKULES Phase 1b/2 trials in 2021 with data readout(s) beginning in 2022 Strengthened executive...
Erasca Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 20, 2021 16:01 ET
|
Erasca, Inc.
SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Announces Pricing of Upsized Initial Public Offering
July 15, 2021 21:58 ET
|
Erasca, Inc.
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...